Cargando…

Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection

Large-cell neuroendocrine carcinoma (LCNEC) is a rare malignancy with poor prognosis. The rationale of the study was to determine the survival of LCNEC patients in I–IIIA clinical stages who underwent resection. A total of 53 LCNEC (89%) and combined LCNEC (11%) patients in stages I–IIIA who underwe...

Descripción completa

Detalles Bibliográficos
Autores principales: Lowczak, Anna, Kolasinska-Cwikla, Agnieszka, Ćwikła, Jarosław B, Osowiecka, Karolina, Palucki, Jakub, Rzepko, Robert, Glinka, Lidka, Doboszyńska, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290504/
https://www.ncbi.nlm.nih.gov/pubmed/32392725
http://dx.doi.org/10.3390/jcm9051370
_version_ 1783545692038365184
author Lowczak, Anna
Kolasinska-Cwikla, Agnieszka
Ćwikła, Jarosław B
Osowiecka, Karolina
Palucki, Jakub
Rzepko, Robert
Glinka, Lidka
Doboszyńska, Anna
author_facet Lowczak, Anna
Kolasinska-Cwikla, Agnieszka
Ćwikła, Jarosław B
Osowiecka, Karolina
Palucki, Jakub
Rzepko, Robert
Glinka, Lidka
Doboszyńska, Anna
author_sort Lowczak, Anna
collection PubMed
description Large-cell neuroendocrine carcinoma (LCNEC) is a rare malignancy with poor prognosis. The rationale of the study was to determine the survival of LCNEC patients in I–IIIA clinical stages who underwent resection. A total of 53 LCNEC (89%) and combined LCNEC (11%) patients in stages I–IIIA who underwent surgery with radical intent between 2002–2018 were included in the current study. Overall survival (OS) and time to recurrence (TTR) were estimated. Uni- and multivariable analyses were conducted using Cox-regression model. Patients were treated with surgery alone (51%), surgery with radiochemotherapy (4%), with radiotherapy (2%), with adjuvant chemotherapy (41%), or with neoadjuvant chemotherapy (2%). The median (95% Confidence Interval (CI)) OS and TTR was 52 months (20.1–102.1 months) and 20 months (7.0–75.6 months), respectively. Patients treated in clinical stage I showed better OS than patients in stages II–IIIA (p = 0.008). Patients with R0 resection margin (negative margin, no tumor at the margin) and without lymph node metastasis had significantly better TTR. In the multivariate analysis, age was an independent factor influencing OS. Recurrence within 1 year was noted in more than half cases of LCNEC. R0 resection margin and N0 status (no lymph node metastasis) were factors improving TTR. Age >64 years was observed as a main independent factor influencing OS.
format Online
Article
Text
id pubmed-7290504
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72905042020-06-17 Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection Lowczak, Anna Kolasinska-Cwikla, Agnieszka Ćwikła, Jarosław B Osowiecka, Karolina Palucki, Jakub Rzepko, Robert Glinka, Lidka Doboszyńska, Anna J Clin Med Article Large-cell neuroendocrine carcinoma (LCNEC) is a rare malignancy with poor prognosis. The rationale of the study was to determine the survival of LCNEC patients in I–IIIA clinical stages who underwent resection. A total of 53 LCNEC (89%) and combined LCNEC (11%) patients in stages I–IIIA who underwent surgery with radical intent between 2002–2018 were included in the current study. Overall survival (OS) and time to recurrence (TTR) were estimated. Uni- and multivariable analyses were conducted using Cox-regression model. Patients were treated with surgery alone (51%), surgery with radiochemotherapy (4%), with radiotherapy (2%), with adjuvant chemotherapy (41%), or with neoadjuvant chemotherapy (2%). The median (95% Confidence Interval (CI)) OS and TTR was 52 months (20.1–102.1 months) and 20 months (7.0–75.6 months), respectively. Patients treated in clinical stage I showed better OS than patients in stages II–IIIA (p = 0.008). Patients with R0 resection margin (negative margin, no tumor at the margin) and without lymph node metastasis had significantly better TTR. In the multivariate analysis, age was an independent factor influencing OS. Recurrence within 1 year was noted in more than half cases of LCNEC. R0 resection margin and N0 status (no lymph node metastasis) were factors improving TTR. Age >64 years was observed as a main independent factor influencing OS. MDPI 2020-05-07 /pmc/articles/PMC7290504/ /pubmed/32392725 http://dx.doi.org/10.3390/jcm9051370 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lowczak, Anna
Kolasinska-Cwikla, Agnieszka
Ćwikła, Jarosław B
Osowiecka, Karolina
Palucki, Jakub
Rzepko, Robert
Glinka, Lidka
Doboszyńska, Anna
Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection
title Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection
title_full Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection
title_fullStr Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection
title_full_unstemmed Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection
title_short Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection
title_sort outcomes of patients with clinical stage i-iiia large-cell neuroendocrine lung cancer treated with resection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290504/
https://www.ncbi.nlm.nih.gov/pubmed/32392725
http://dx.doi.org/10.3390/jcm9051370
work_keys_str_mv AT lowczakanna outcomesofpatientswithclinicalstageiiiialargecellneuroendocrinelungcancertreatedwithresection
AT kolasinskacwiklaagnieszka outcomesofpatientswithclinicalstageiiiialargecellneuroendocrinelungcancertreatedwithresection
AT cwikłajarosławb outcomesofpatientswithclinicalstageiiiialargecellneuroendocrinelungcancertreatedwithresection
AT osowieckakarolina outcomesofpatientswithclinicalstageiiiialargecellneuroendocrinelungcancertreatedwithresection
AT paluckijakub outcomesofpatientswithclinicalstageiiiialargecellneuroendocrinelungcancertreatedwithresection
AT rzepkorobert outcomesofpatientswithclinicalstageiiiialargecellneuroendocrinelungcancertreatedwithresection
AT glinkalidka outcomesofpatientswithclinicalstageiiiialargecellneuroendocrinelungcancertreatedwithresection
AT doboszynskaanna outcomesofpatientswithclinicalstageiiiialargecellneuroendocrinelungcancertreatedwithresection